Title of Research: 16_S01-02
Prediction method (Amino acid Derivative Reactivity Assay: ADRA) for skin sensitization using novel lysine and cysteine derivatives

Principal Investigator:
Toshihiko Kasahara, PhD (Engineering Manager, FUJIFILM Corporation, Safety Evaluation Center, Ecology & Quality Management Division, CSR Division)
210, Nakanuma, Minamiashigara-shi, Kanagawa 250-0193, Japan
tel +81-465-73-7440 (e-mail)ktoshihiko.kasahara@fujifilm.com

Collaborators:
Masaharu Fujita, PhD (FUJIFILM Corporation, Safety Evaluation Center)
210, Nakanuma, Minamiashigara-shi, Kanagawa 250-0193, Japan
tel +81-465-73-7440 (e-mail)masaharu.fujita@fujifilm.com

Yusuke Yamamoto (FUJIFILM Corporation, Safety Evaluation Center)
210, Nakanuma, Minamiashigara-shi, Kanagawa 250-0193, Japan
tel +81-465-73-7440 (e-mail)yusuke.yamamoto@fujifilm.com

Atsushi Ono, PhD (Professor, Okayama University, Graduate school of Medicine, Dentistry and Pharmaceutical sciences, Division of Pharmaceutical Sciences)
1-1-1, Tsushimanaka, Kita-ku, Okayama-shi, Okayama 700-8530, Japan
tel 086-251-7942 (e-mail)atsushio3@okayama-u.ac.jp

Hajime Kojima, PhD (Director, National Institute of Health Sciences, Biological safety Research Center, Division of Risk Assessment)
1-18-1, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan
tel 03-3700-9874 (e-mail)h-kojima@nihs.go.jp

Shinichi Wantanabe (LION CORPORATION, HUMAN & ENVIRONMENTAL SAFETY EVALUATION CENTER)
100, Tajima, Odawara-shi, Kanagawa 256-0811
tel 0465-49-4475 (e-mail)shin-w@lion.co.jp

Tsunetsugu Sugawara (LION CORPORATION, HUMAN & ENVIRONMENTAL SAFETY EVALUATION CENTER)
100, Tajima, Odawara-shi, Kanagawa 256-0811
tel 0465-49-4475 (e-mail)tsune-s@lion.co.jp

Koji Wakabayashi (Manager, MITSUI CHEMICALS, INC., Chemical Safety Department)
1144, Togo, Mobara-shi, Chiba 297-0017, Japan
tel 0475-23-8251 (e-mail)Koji.Wakabayashi@mitsuichemicals.com

Yu Tahara (MITSUI CHEMICALS, INC., Chemical Safety Department)
1144, Togo, Mobara-shi, Chiba 297-0017, Japan
tel 0475-23-8251 (e-mail)Yu.Tahara@mitsuichemicals.com

Nobuyuki Horie (Senior Research Scientist, SUMITOMO Chemical Co., Ltd., Environmental Health Science Laboratory)
3-1-98, Kasugadenaka, Konohana-ku, Osaka-shi, Osaka 554-8558, Japan
tel 06-6466-5107 (e-mail)horien@sc.sumitomo-chem.co.jp

Keiichi Fujimoto (SUMITOMO CHEMICAL Co., Ltd., Environmental Health Science Laboratory)
3-1-98, Kasugadenaka, Konohana-ku, Osaka-shi, Osaka 554-8558, Japan
tel 06-6439-9753 (e-mail)fujimotoki2@sc.sumitomo-chem.co.jp

Kei Kusakari (NISSAN CHEMICAL INDUSTRIES, LTD. Biological Research Laboratories)
1470, Shiraoka, Shiraoka-shi, Saitama 349-0294, Japan
tel 0480-92-2513 (e-mail)kusakarik@nissanchem.co.jp

Yoshihiko Kurokawa (NISSAN CHEMICAL INDUSTRIES, LTD. Biological Research Laboratories)
1470, Shiraoka, Shiraoka-shi, Saitama 349-0294, Japan
tel 0480-92-2513 (e-mail)kurokawayo@nissanchem.co.jp
Summary of Research:

In this study, we performed the validation study so that the alternative method for skin sensitization (ADRA) is adopted as OECD test guideline.

For the four participating laboratories, the two training sessions were held, and the two confirmation tests (Pre-training test and Training test) were performed because the lead laboratory confirmed that the assay technique was correctly transferred for the participating laboratories.

The Pre-training test was performed using 5 test chemicals to be easy to be categorized correctly. The predictive results for 5 chemicals at four participating laboratories were completely consistent with the results at lead laboratory, so it was thought that the first step of technical transfer was finished. The Training test was performed using 10 test chemicals that would be difficult to be categorized correctly. The Within-Laboratory Reproducibility at each laboratory were 100%, 90%, 100% and 100%, respectively, and so it was thought that technical transfer was completely finished because the goal was accomplished.

It was decided at VMT meeting that Phase-1 study (as Within-Laboratory Reproducibility) would be performed using three replicate sets of 10 chemicals and Phase-2 (as Between-Laboratory Reproducibility) study would be performed using one set of 30 chemicals in the ADRA validation study. The Within-Laboratory Reproducibility at each laboratory were 100%, 90%, 100% and 100%, respectively, and these values were higher than expected in that the results of Phase-1 achieved the Within-Laboratory Reproducibility of more than 80% of target.

After Phase-1 validation study, VMT teleconference was held on January in 2019, and VMT member were evaluated the results of Phase-1 study. Because all the improvement items proposed by lead laboratory were approved by VMT members, and the Phase-2 study was started on February in 2019 as scheduled.
Timeline: March 1, 2016–

Topics:
1. Presented at ICCA–LRI & NIHS WORKSHOP–Awaji Island, Japan 「Validation study on Amino acid Derivative Reactivity Assay (ADRA) for prediction of skin sensitization」

Publications:
1. Presented at the 29th Annual Meeting of the Japanese Society of Alternatives to Animal Experiments (November 18, 2016) 「Reporting of Training and Transfer Outcome for Validation Study of Alternative Method (ADRA) for Skin Sensitization using Cys and Lys Derivatives」
2. Planned to be presented at the 44th Annual Meeting of the Japanese Society of Toxicology (July 10-12, 2017) 「Multicenter Validation Study of Novel in chemico Skin Sensitization Assay (ADRA): 1st Report」